estrogen receptor inhibitor

The estrogen receptor inhibitor program, developed by the Department of Thoracic Surgery at Tongji Hospital (Huazhong University of Science and Technology), focuses on the inhibition of estrogen signaling as a therapeutic strategy for non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma. Research from this institution has demonstrated that estrogen receptors, specifically the alpha (ERα) and beta (ERβ) isoforms, are expressed in lung cancer tissues and contribute to tumor cell proliferation, survival, and migration. By utilizing estrogen receptor antagonists, the program aims to disrupt both the classical genomic signaling pathway and the rapid non-genomic crosstalk with other oncogenic pathways, such as the EGFR signaling axis. This therapeutic approach is being investigated in both preclinical and clinical settings, often in combination with tyrosine kinase inhibitors or chemotherapy, to improve clinical outcomes and overcome treatment resistance in patients with advanced lung cancer.

Other names

estrogen receptor antagonistER inhibitor